NCT04820023 2025-06-06
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
Bridge Biotherapeutics, Inc.
Phase 1/2 Terminated
Bridge Biotherapeutics, Inc.
Spectrum Pharmaceuticals, Inc
EQRx International, Inc.
HiberCell, Inc.